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ABSTRACT
The ret proto-oncogene codes for a receptor tyrosine kinase involved in the pathogenesis of nu­
merous developmental defects, particularly those in neural crest-derived structures leading to the 
regulation of cell proliferation, migration, differentiation and survival during embryogenesis. 
Constitutive activation or inactivation of the RET receptor results in the cancer syndrome Multi­
ple Endocrine Neoplasia or Hirschsprung's disease, respectively. The importance of RET in these 
disease states has been well established. However, while many proteins associated with the RET 
signaling pathway have been identified, the transcriptional changes induced by the wild type re­
ceptor, particularly with respect to these signaling proteins in neuroblastoma cells, is less clear. In 
order to better understand the transcriptional changes that occur in response to RET activation, 
SK-N-SH neuroblastoma cells were treated with 100 ng/ml GDNF and the RNA isolated. Focus­
ing on the changes in transcription of specific genes that occur in response to the activation of 
RET, including Etv4, Spryl and Shp2, primers for these genes were designed and the genes char­
acterized using standard RT-PCR and then further analyzed using real-time PGR. Some of these 
genes promote and control branching in kidney morphology while others, when mutated, are as­
sociated with several human diseases. Analyzing the expression levels of each gene in response to 
the activation of RET will aid in elucidating RET-mediated mechanisms that contribute to these 
diseases and understanding the role of RET on downstream signaling and cellular function.
These findings show quantitatively minimal effect on Spryl, Shp2 and Etv4 expression in re­
sponse to 4-hour GDNF treatment in neuroblastoma cells by real-time PGR. Because the fold 
changes observed were not remarkable, the data suggests that expression regulation of these pro­
teins may not be dependent on RET activation. Future studies include analyzing transcriptional 
changes of these signaling proteins in response to RET activation with longer GDNF treatments
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or by combination of different ligand stimulation to help further elucidate the possible role of 
RET on these signaling proteins.
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INTRODUCTION
STRUCTURE of RECEPTOR TYROSINE KINASES
Cells have the ability to sense cues in their environment, process these cues and respond accord­
ingly. Such processes are mediated through a diverse group of cell surface receptors, including a 
group called receptor tyrosine kinases (RTKs). RTKs represent a family of proteins present in all 
metazoans that have been conserved over evolutionary time because of their ability to contribute 
to the fitness of the organism in which they are expressed. The conservation of RTKs in mam­
mals suggest that each is responsible for cellular communication to regulate different cellular pro­
cesses including proliferation, differentiation, migration, survival, protein synthesis, metabolism 
and other cellular outcomes. The study of orthologs of human proteins in the nematode worm 
Caenorhabditis elegans elude to their respective functions in both species. The structure of RTKs is 
highly conserved from the C. elegans, and is described as an extracellular domain containing a lig­
and-binding site, a single hydrophobic transmembrane domain and an intracellular catalytic do­
main with protein tyrosine kinase activity. The kinase gene in C. elegans describes the mechanism 
by which RTKs have driven their evolution by gene duplication and thus, the mechanisms that 
influence evolution (Popovici et ah, 1999).
Gene duplication highlights one of the main reasons for the extensive RTKs identified in the hu­
man genome (Yarden and Wheeler, 2015). In gene duplication, two identical copies exist for a 
particular function that was originally fulfilled by one copy. Consequently, only one copy is con­
sidered functional while the other is considered dispensable. The dispensable copy can either ac­
quire mutations that may impair its function, or evolve an acquired function. The acquired func­
tion will remain as a paralogue of the original gene and may be expressed in different cell types, 
may be activated by different ligands or become involved in related signaling pathways. Other­
wise, the dispensable copy and the functional copy can share the function of the ancestral gene.
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The gene sequence similarities across these three possible outcomes give rise to the RTK gene 
families.
Takahashi et. al., first identified the c-ret protooncogene as part of an oncogenic fusion protein 
resulting from a translocation assay in vitro (Takahashi et al., 1985). The gene, named rearranged 
during transfection (ret) was found to encode a structurally unique transmembrane receptor tyro­
sine kinase. Characterization of the gene, on human chromosome lOql 1.2, revealed the primary 
structure of the RET protein (figure 1): an extracellular region consisting of four cadherin-like 
domains including a calcium binding site, the cysteine-rich extracellular domain that mediates co­
receptor and ligand binding, a hydrophobic transmembrane domain and the intracellular catalyt­
ic tyrosine kinase domain with two flanking regulatory regions, the junxtamembrane and C-tail 
with tyrosine residue phosphorylation sites (Takahashi et al. 1988; Anders et al. 2001). Alternative 
splicing of the protein gives rise to two functionally distinct isoforms of RET that differ in their 
respective C-terminus tail, named RET 9 and RET 51 (Tahira et al., 1990).
The RET proto-oncogene represent a receptor tyrosine kinase. There are 90 tyrosine kinase 
genes in the human genome, of which 58 encode receptor tyrosine kinases (Robinson et al., 2000). 
The catalytic tyrosine kinase domain is the most conserved part of RET with 90 percent sequence 
similarity to vertebrate lineages and, to a lesser extent, the extracellular domain with 40 percent 
sequence similarity with RET vertebrate species (Hahn and Bishop, 2001). The cysteine rich do­
main (CRD) found within the extracellular domain of RET represents a homologous structural 
motif used to identify RET in lower organisms (Takahashi, 2001). Fourteen of the twenty-eight 
cysteines are conserved between human, zebrafish and Drosophila species (Hahn and Bishop, 
2001). Studies have traced the evolutionary conservation of the RET protein sequence and its 
expression in development across different organisms. Expression of endogenous RET has been
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described in cells originating from the neural ectoderm termed the neural crest. In D. melanogaster, 
the fruit fly, minimal amounts of RET are found in embryonic, larval and pupil stages (Sugaya et 
al., 1994). RET is also expressed in the late embryo in subpopulations of the central nervous sys­
tem and peripheral nervous system (Sugaya et al., 1994). In B. ranio, the zebrafish, RET is detect­
ed in the nervous system and excretory system. In the nervous system, RET is found in primary 
and motor neurons as well as neural crest cells and ganglion cells. In the excretory system, RET 
is present in the developing functional part of the kidney, termed the nephron duct (Marcos- 
Gutierrez etal., 1997).
The two isoforms of the RET protein are expressed in higher organisms such as the chicken, 
mouse and human. The catalytic domain of the chicken is 91 percent similar to the human RET 
protein while the extracellular domain is 68 percent similar to human RET (Marcos-Gutierrez et 
al., 1997). The cysteine residues present in the extracellular domain of the chicken RET protein 
suggest the residues represent a conserved structure. During chicken embryogenesis, RET is ex­
pressed in sites of the nervous system and excretory system (Schuchardt et al., 1995). In addition, 
RET is found in the development of the ventral roots of the spinal cord, the mesenchymal cells 
and adult testes (Schuchardt et al., 1995), eluding to the role of RET in early development. Fur­
ther, the extracellular and catalytic domains are similar in structure in both the mouse and human 
RET proteins. The nucleotide sequence of the mouse RET protein is 83 percent similar to the 
human RET protein (Iwamoto et al., 1993). The similarities in RET expression between higher 
and lower organisms suggest the function of RET has been conserved during evolutionary time. 
The extent of homology between vertebrate and invertebrate species suggests RET may function 
similarly in terms of downstream signaling patterns across the organisms (Abrescia et al., 2005).
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MODES of RECEPTOR ACTIVATION
Signaling pathways begin with a ligand binding to a receptor. While there are many receptors on 
the surface of a cell, the receptor will only bind to a specific ligand or set of ligands. The signal­
ing molecule, which can be a functional group, growth factor, neurotransmitter, antigen or a hor­
mone behaves as a ligand to change the properties of the receptor. Most signaling molecules are 
water-soluble and cannot bypass the cell membrane without binding to a cell surface receptor. 
After a ligand binds to a cell surface receptor, other processes, such as internalization, degradation 
or recycling can determine which signaling pathway is activated or deactivated as well as the du­
ration of the signal (Ullrich and Schlessinger, 1990). Ligand binding is necessary to stabilize the 
receptor regardless of whether the receptor is monomeric or oligomeric in its inactive state, but 
activation may also occur in the absence of the ligand. Most commonly, growth factor binding 
activates the receptor by inducing dimerization (Ullrich and Schlessinger, 1990).
RET is the signaling receptor for the glial-cell derived neurotrophic factor (GDNF) family of sol­
uble, covalent, dimeric ligands (Trupp et al., 1996; Treanor et al., 1996; Durbec et al., 1996). 
GDNF was initially identified as a trophic factor for dopaminergic neurons (Lin et al., 1993) and 
later found involved in survival of sensory and motor neurons of the enteric nervous system 
(Baloh et al., 2000). The four proteins, GDNF, Neurturin (NTN), Persephin (PSP) and Artemin 
(ART) have been renamed GDNF family ligands (GFLs) (Baloh et al., 2000). This family of pro­
teins form a subdivision of the transforming growth factor (3 (TGF-J3) superfamily, being the only 
members of that family to signal via a RTK (Mason, Ivor, 2000). NTN, PSP and ART share simi­
lar characteristic to that of GDNF. However, GFLs do not bind to the extracellular domain of 
RET directly. They bind indirectly by first forming a complex with one of the four glycosly-phos- 
phatidylinositol (GPI) anchored GFRa co-receptors (GFRal-4). The ligand binds to the co-re- 
ceptor based on high affinity to form the following complexes: GDNF —» GFRal; NTN —*
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GFRa2; ART —> GFRa3; and PSP —* GFRa4 (Mason, Ivor, 2000). Although each GFL ligand
exhibits a preference for a specific GFRa co-receptor, different complexes may be formed depen­
dent on the receptor and co-receptor localization. Other functional complexes formed based on 
low affinity: GDNF —» GFRa2; NTN —» GFRal; ART —> G FRal may also activate RET 
(Trupp et ah, 1996; Mason, Ivor, 2000).
The receptor’s signal transduction is dependent on the assistance of lipid rafts on the plasma 
membrane. The complex formation between the ligand, co-receptor and receptor is mediated by 
the scaffolding properties of lipid rafts on the cell membrane. Jing et al., 1996 described the RET 
receptor complex formation with respect to the lipid rafts in two different ways. First, the dimeric 
GFL ligand ligates the two monomers of the GFRa co-receptor, which are commonly located in 
the lipid raft. Alternatively, the GFRa co-receptor is cleaved from the plasma membrane to pro­
duce a soluble form that associates with the dimeric GFL ligand. The complex then recruits RET 
to the lipid raft and promotes its homodimerization, which in turn, leads to activation. Dimeriza­
tion of RET can stimulate autophosphorylation of specific tyrosine residues on the intracellular 
catalytic domain.
The activation mechanism by which ligand-induced dimerization leads to kinase activation differs 
for the particular RTK. The activation loop of the kinase domain in RTKs adopts a conforma­
tional change that mediates phosphotransferase catalytic activity. Protein kinases catalyze the 
transfer of the gamma phosphate group from adenosine triphosphate to a tyrosine residue on a 
substrate protein. Protein phosphatases transfer the phosphate group from a phosphoprotein to a 
water molecule. Such enzymes are termed phosphotransferases and catalyze opposing reactions 
to mediate kinase domain activity. Protein phosphorylation and dephosphorylation are a signal­
ing motif that defines RTK activation. The crystal structures of the activated kinase domains of
Page 14 of 85
RTKs are very similar because all kinase domains include an N and C-terminal lobe. The crystal 
structures of the inactivated kinase domains differ across RTKs, suggesting they may regulate in 
different ways (Huse and Kuriyan, 2002). In unstimulated conditions, the catalytic domains of 
most kinases are monomeric and auto-inhibited in cis by the C-lobe activation loop that keeps the 
kinase pocket closed. In stimulated conditions, inhibition is relived and the receptor is activated 
by the binding of specific ligands that stimulate the receptor’s protein tyrosine kinase activity (Ull­
rich and Schlessinger, 1990).
The RET intracellular catalytic tyrosine kinase domain is predicted to adopt the classical fold con­
formation involving the N-terminal lobe and C-terminal lobe connected by the linker region 
(Knowles et ah, 2006). Instead of a cis conformation, RET adopts a trans conformation that 
blocks the substrate binding site of each monomer within the inactive dimer (Knowles et al.,
2006). Ligand growth factor stimulation brings the two intracellular parts of the RET homo­
dimer in proximity of one another, such that, the auto-inhibitory constraints are relieved, thereby 
favoring the formation of an active dimer that allows for catalytic activity of the kinase domain. 
The catalytic activity of the kinase domain that leads to different signaling pathways is described 
by the phosphorylation of specific tyrosine residues. 7rarcj-autophosphorylation can be divided 
into two parts each with specific catalytic properties. The first wave of phosphorylation serves to 
enhance the catalytic activity of the kinase once the receptor binds to its ligand. The second wave 
creates the phophotyrosine binding sites that recruit cytoplasmic signaling molecules that include 
binding domains. The resulting phosphotyrosines serve as docking sites for other protein-protein 
interactions involved in the RTK-mediated signaling pathway.
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RET in DISEASE and DEVELOPMENT
RET plays an essential role in development of the nervous and enteric systems, and in signaling 
during development of the mammalian kidney. The neural crest cells originate in the dorsal most 
part of the neural tube and migrate extensively to generate differentiated cell types including sub­
populations of the enteric, sensory and sympathetic nervous systems (Pachnis et ah, 1993). The 
different substitutions and rearrangements in the ret gene underlie various human diseases includ­
ing four different human cancers: papillary thyroid carcinoma (PTC), familial medullary thyroid 
carcinoma (MTC) and multiple endocrine neoplasia types 2A and 2B (MEN 2A and MEN 2B) 
(Grieco et al., 1990; Donis-Keller, Helen, et al. 1993; Mulligan et ah, 1993; Hofstra et ah, 1994).
A chromosomal rearrangement of RET leads to oncogenic properties of the protein present in 
human papillary thyroid carcinomas (PTC) (Grieco et al., 1990).
MTC is a cancer syndrome that affects tissues derived from the neural ectoderm, specifically 
glands of the endocrine system. MTCs are rare tumors of the neural crest that arise from calci­
tonin secretion by a subset of cells in the thyroid glands named parafollicular C cells. MTC is 
classified into three types: familial MTC, MEN 2A and MEN 2B, and are characterized by the 
types of tumors and the age of onset of the disease (Donis-Keller, Helen, et al. 1993; Santoro et 
al., 1995). Mutations to RET account for a quarter of inherited MTCs that are either sporadic or 
familial. Sporadic MTC arises from somatic mutations of the RET protein and generally 
presents as a tumor confined to one thyroid lobe. Familial MTC results from germ-line mutations 
of the RET protein and often present as bilateral tumors (Donis-Keller, Helen, et al. 1993; San­
toro et al., 1995).
MEN2 is a hereditary cancer defined by defects to major glands of the endocrine system includ­
ing the thyroid, parathyroid and adrenal glands. MEN 2A usually occurs during early adulthood
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and is characterized by MTC and tumors of the adrenal gland and neuroendocrine tissues named 
phaeochromocytoma (Donis-Keller, Helen, et al. 1993; Mulligan et al., 1993). The MEN 2A 
gene has been mapped to the DNA sequence on chromosome lOql 1.2 that also encompasses the 
RET protein (Gardner et al., 1993J. Germ-line missense mutations of RET have been identified 
in the majority of different MEN 2A families (Mulligan et al., 1993). The RET mutations associ­
ated with MEN 2A are the cysteine residues 609, 611, 618, 620, 630 and 634. The majority of 
mutations identified affect the same conserved cysteine residue 634 located on RET’s extracellular 
domain suggesting RET as a target for the MEN 2A gene (Mulligan et al., 1993). In the absence 
of the ligand, MEN 2A mutations leave an unpaired cysteine residue leading to the constitutive 
dimerization of the RET monomers by intramolecular disulfide bonds, followed by constitutive 
activation of the kinase domain (Santoro et al., 1995).
MEN 2B usually occurs in infancy or early childhood and is characterized by MTC and 
pheochromocytoma, but also by mucosal neuromas and ganglioneuromas, which are tumors 
composed of ganglion cells and nerve fibers of the gastrointestinal tract. MEN 2B has also been 
associated with mutations of the RET proto-oncogene by a substitution of a threonine for a me­
thionine in the tyrosine kinase catalytic domain of the protein (Hofstra et al., 1994). The muta­
tion that accounts for most of MEN 2B is mapped to the residue 918 in the catalytic domain of 
RET. This mutation induces conformation change of the kinase domain, resulting in activation 
of RET protein without dimerization (Iwashita et al., 1996). The different point mutations in 
MEN 2A, MEN 2B and FMTC that activate RET and disrupt development of the peripheral 
nervous system are described as gain-of-function mutations.
The enteric nervous system (ENS) derives from neural crest cells, which migrate and differentiate 
in the mesenchyme of the developing gut and subsequently become the gastrointestinal tract.
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Hirschsprung disease (HSCR) is a congenital, genetic disorder of the neural crest development 
characterized by the absence of enteric parasympathetic neurons in the lower end of the gut. 
While the RET mutations that underline the cancer syndromes are described as gain-of-function 
mutations, HSCR is described by the inactivation of RET therefore are considered loss-of-func- 
tion germ-line mutations (Schuchardt et al., 1994; Romeo et al., 1994). The disease is described as 
a blockage of the large intestine due to poor muscle movement caused by lack of nerves in the 
bowel and thus, results in an enlargement of the bowel and abdomen areas. Different types of 
mutation to the RET protein result in the HSCR phenotype. Missense and frameshift mutations 
found in the tyrosine kinase domain of RET show a decrease of kinase activity that is consistent 
with the HSCR phenotype (Romeo et al., 1994). Mutations to the extracellular domain inhibit 
RET’s cell surface expression caused by incorrect folding of the protein (Iwashita et al., 1996). 
Consequently, RET-mediated signaling pathways are impaired. Thus, RET signals are essential 
for the normal development of the enteric nervous system.
Besides RET’s role in the peripheral and enteric nervous system, it also plays a role in developing 
mammalian kidney. As described by (Pietila et al., 2013), the development of the mammalian 
kidney progresses through three stages, of which two are transient and the last remains as the 
functional kidney. An important step in kidney development is the formation of the Wolffian duct 
which can be defined as a simple epithelial tube from a group of cells that undergo mesenchyme- 
to-epithelial transition in the mesoderm. A subset of cells adjacent to the group that give rise to 
the Wolffian duct, gives rise to the non-functional primitive kidney, the pronephros. The 
pronephros eventually degenerates and then the next kidney, the mesonephros begins to form.
The mesonephros consists of tubules that are connected peripherally to the Wolffian duct. The 
mesonephros is also a transient structure because it later regresses to become part of the epi­
didymis in males and the metanephros remains as the predominant kidney structure present in
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adult mammals. The metanephros appears as a tubular outgrowth of the Wolffian duct, known 
as the ureteric bud (UB), that invaginated the metanephric mesenchyme in a process knows as UB 
induction. While in the metanephric mesenchyme, the UB folds into a T-shaped structure with 
two tips and a stalk and each subsequent tip continues to grow in a process termed branching 
morphogenesis. Branching morphogenesis is led by interactive signaling between the UB epithe­
lium and metanephric mesenchyme to become the collecting system of the kidney. Formation of 
the kidney is completed before birth in humans, but continues after birth in mice.
Gene-targeting studies revealed the G D N F/G FRal/RET signaling complex is physiologically 
essential in different stages of kidney development. In mice, the proliferating Wolffian duct is 
filled with cells that express RET and GFRal. RET-GFRal-expressing cells undergo cellular 
rearrangement prior to migrating to what will become the UB (Pachnis et al., 1993; Cacalano et 
al., 1998). GFRal-GDNF-expressing cells are located in the mesenchyme of the urinary system 
adjacent to the Wolffian duct (Hellmich et al, 1996; Cacalano et al., 1998). The UB outgrowth 
from the Wolffian duct is induced by GDNF signals from the mesenchyme and GDNF is proposed 
to control the growth of the UB tips during branching morphogenesis (Vega et al., 1996). The 
proliferating UB has the greatest amount of RET-GFRal expression while the UB stalk harbors 
the least RET-GFRal expression (Schuchardt et al., 1994; Cacalano et al., 1998). During 
branching morphogenesis, the UB fold is led by the high concentration of RET-expressing cells at 
the distal UB tips (Pachnis et al., 1993). At this stage in development, the expression of GFRal in 
the UB is much greater than that of the mesenchyme (Keefe et al., 2013). The expression of 
RET-GFRal becomes weaker in the UB stalk, the ureter bud epithelium and the Wolffian duct as 
the common nephron duct (CND) forms (Hoshi et al., 2012).
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Mutations in RET are associated with congenital anomalies of the kidney and urinary tract 
(CAKUT) and these mutations have been revealed in three different in vivo experimental ap­
proaches in mice. In the first approach, aberrant expression of RET caused multi-cystic dysplas- 
tic kidneys where the renal cortex is replaced by cysts during fetal development leading to a non­
functional kidney (Srinivas et ah, 1999). In the second approach, nonfunctional RET and the ab­
sence of G FRal caused downregulation of Erk in the Ras-Erk/MAPK pathway which resulted 
in unilateral or bilateral renal agenesis, or kidney hypoplasia due to failure of the ureteric bud to 
evaginate from the Wolffian duct and branch properly (Jain et al., 2004). In the last approach, 
both isoforms of RET, promoted branching morphogenesis to an extent, but mutations in the 
tyrosine residues ,Y1062, Y1015 and Y981, resulted in renal defects for RET 9 and not for RET 
51 (Jain et al., 2006). The absence of Y1062 in kidney development disrupted the Ras-Erk/ 
MAPK and PI3K/Akt pathways. The absence of Y1062 and Grb2 in RET 9 resulted in bilateral 
renal agenesis, a phenotype similar to non-functional RET mutations in mice. However, the ab­
sence of Y1062 in RET 51 did not affect kidney development. The absence of the Src and Grb2 
adaptors on Y981 in RET 9 resulted in unilateral or bilateral kidney agenesis. Conversely, the 
absence of Src on Y981 in RET 51 resulted in normal kidneys. Moreover, loss of Y1015 signal­
ing in RET prevents association with the adaptor phospholipase C gamma (PLC-y). Lack of
PLC-)' recruitment resulted in renal dysplasia described by multiplexed kidneys, enlarged ureters
and failure of gonads to properly develop in male and females (Jain et al., 2006). RET 51 pro­
vides redundancy and promotes normal kidney formation via Y1096 when there are mutations to 
Y981 orY1062 (de Graaff etal., 2001; Jain et al., 2006).
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THE SIGNALING PATHWAYS ACTIVATED by RET
RTK signaling is described as an interconnected network because of the many phosphorylation 
sites present in the intracellular domain of RTKs and the multiple signaling proteins that may be 
recruited at those individual phosphorylation sites. The signaling molecules may be recruited to 
the phosphotyrosines in the receptor via receptor-proximal interactions such as Src homology 2 
(SH2) and phosphotyrosine binding (PTB) binding domains (Schlessinger and Lemmon, 2003). 
There are approximately 100 SH2 domains that have been identified in the human genome and 
these domains mediate phosphorylation dependent protein-protein interactions. The signaling 
molecules are adaptor proteins that contain these binding domains with a conserved binding- 
pocket that specifically attaches to the autophosphorylated tyrosine residues present on the recep­
tor. The formation of a signaling complex occurs when a signaling protein containing an SH2 or 
PTB domain binds directly or indirectly to a specific autophosphorylation site on the receptor.
Cells contain many proteins with SH2 and PTB domains that bind to phosphorylated tyrosine 
residues including adaptor proteins, docking proteins, transcription factors and enzymes. Adaptor 
proteins, such as growth factor receptor-bound protein 2 (Grb2), function as linkers that allow two 
signaling proteins to bind together to form a signaling complex. Docking proteins, such as fibrob­
last growth factor receptor substrate 2 (FRS2), insulin receptor substrate-1 (IRS1) and Grb2 asso­
ciated binding proteins (GAB) provide receptors with additional tyrosine phosphorylation sites 
and these interactions that are spatially and temporally removed function as binding sites for other 
signaling proteins. (Schlessinger and Lemmon, 2003). Transcription factors may also bind to the 
activated receptor and subsequently become translocated to the nucleus such as members of the 
signal transducers and activators of transcription, (STAT) family. Enzymes such as (PLC-y), a
lipid phosphoinositide 3-kinase (PI3K) and a protein tyrosine phosphatase (SHP2) may also be­
come become activated by binding to an activated receptor (Schlessinger and Lemmon 2010).
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RET regulates proliferation, differentiation, migration, survival, protein synthesis and other cellu­
lar processes as a result of downstream signaling pathways, including Ras-Erk/MAPK, PLC-y,
PKC, PI3K/Akt, JAK/STAT, RAG1 andJNK (figure 2). The alternative splicing of the RET 
protein adds complexity to the mechanism by which RET signals. The She proteins bind to both 
of the RET isoforms. However, RET 9 will only associate with the SH2 binding domain whereas 
RET 51 will only associate with the PTB binding domain of She adaptor proteins (Lorenzo et al., 
1997), suggesting differences in downstream signaling and regulation of cellular interactions.
Previous studies showed that 14 out of 18 tyrosine residues present in the intracellular cytoplasmic 
region of RET can become autophosphorylated (Liu et al., 1996). The tyrosine residues Y905, 
Y981, Y1015, Y1062, and Y1096 are important for further signaling propagation because each of 
theses sites allow for multiple adaptor proteins including Src (Y981), Grb7/10 (Y905), PLC-y
(Y1015), Shc/IRSl or IRS2/DOKl,2,4,5 or DOK6 (Y1062) and Grb2/GABlor GAB2 (Y1096) 
to associate with activated RET (Mason, Ivor, 2000). Amongst these, Y1015 and Y1062 have 
been shown to be important for ligand-dependent and ligand-independent activation of RET 
(Takahashi, 2001). Some of these adaptor proteins bind to the activated RET within the lipid 
raft, while others prefer to bind to RET outside of the lipid raft. These binding sites have either 
redundant or unique roles that are dependent on the tissue and cell type.
Apart from tyrosine autophosphorylation, other autophosphorylation sites contribute to RET ac­
tivation. The serine residue, S696, is associated with protein kinase A (PKA) (Fukuda et al., 2002). 
Mutations of this residue affect the ability of RET to activate the small GTPase Rac 1 and to in­
duce formation of a flattened extension of a cell termed lamellipodia, that is important for cell 
motility during cell migration (Fukuda et al., 2002). Alternatively, the S696 residue leads to the
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activation of the JNK pathway through binding of the PKA adaptor protein. In addition, activa­
tion of PKA by forskolin, a chemical found in Plectranthus barbatus (Coleus forskohlii), was found to 
block the recruitment of SHP2 to RET and negatively affect the ligand growth factor stimulation 
(Perrinjaquet et ah, 2010). Moreover, mutations to S687 promote SHP2 binding to the receptor 
and cancel the negative effects caused by forskolin.
The first tyrosine residue after the serine residue on the receptor that may become phosphorylated 
is Y687. The tyrosine residue, Y687, is mapped to the junxtamembrane region of the RET in­
tracellular domain (Perrinjaquet et ak, 2010). Upon growth factor stimulation, tyrosine-protein 
phosphatase non-receptor type 11 (PTPN11), which is the gene that in humans encodes the SHP2 
protein, binds to Y687, but is not linked to the transduction of a signaling pathway directly asso­
ciated with RET. The following tyrosine residue that can become phosphorylated is Y786. Phos­
phorylation of Y786 leads to the recruitment of the SHP2 and activation of the PI3K/Akt path­
way. The PI3K/Akt pathway may be activated upon the recruitment of SHP2 to Y786 on the 
activated receptor, but also with cooperative binding of Y1062. Both of the tyrosine residues 
Y786 and Y 1062 are necessary for stable recruitment of SHP2 to the receptor to activate the 
PI3K/Akt pathway (Perrinjaquet et al., 2010). SHP2 may promote survival and neurite out­
growth in primary neurons through the binding of phosphotyrosine Y786 (Perrinjaquet et ak, 
2010).
There are two tyrosine residues, Y900 and Y905, that map to the activation loop of the RET ty­
rosine kinase domain and undergo autophosphorylation (Knowles et ak, 2006). The growth fac­
tor receptor-bound protein 7 (Grb7) and protein growth factor receptor-bound protein (GrblO) 
bind to the phosphotyrosine Y905 to induce signaling of the Ras-Erk/MAPK pathway. Following 
Y905 is Y981 which can also become phosphorylated. The tyrosine residue, Y981, binds to the
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Src cytoplasmic tyrosine kinase and leads to the activation of the PI3K/Akt pathway (Encinas et 
al., 2004). Most recently Y981 was found to associate with Rap 1 GAP for RET binding and sup­
press growth factor induced stimulation of Erk and neurite outgrowth (Jiao et ah, 2011). Finally, 
the recruitment and phosphorylation of SHC adaptors to phosphotyrosine Y 1015 leads to the 
binding of PLC-y and activation of the protein kinase C (PKC) (Borrello et ah, 1996).
The most well-characterized site on all of the RET protein’s isoforms is the tyrosine residue 
Y1062. Upon ligand growth factor stimulation, two different protein complexes assemble on the 
phosphorylated Y1062 via the Shcl transforming protein 1 (Asai et ah, 1996; Lorenzo et ah,
1997). One of the signaling complexes leads to the activation of the PI3K/Akt pathway through 
the recruitment of the adaptor proteins Grb2 and Gabl or Gab2 (Besset et ah, 2000). The sec­
ond signaling complex formation leads to the activation of the Ras-Erk/MAPK pathway through 
the recruitment and phosphorylation of adaptor proteins Grb2 and/or Gab lor Gab2 (Besset et 
al., 2000). Alternatively, FRS2 associates with Y1062 in competition with Shcl and leads to the 
activation of the Ras-Erk/MAPK pathway through the recruitment of the adaptor proteins Grb2 
and sons of sevenless (SOS) (Kurokawa et al., 2001). The JNK pathway is activated upon binding 
of docking protein 1 (Dokl) and non-catalytic region of tyrosine kinase adaptor protein (Nek) to 
Y1062 (Murakami et al., 2002). The adaptor proteins IRS1, IRS2 and docking proteins Dok2, 
Dok4, Dok5 and Dok6 are also associated with Y1062 (Melillo et al., 2001; Grimm et al., 2001). 
Tyrosine residue Y1062 is important for RET function and has been shown to induce severe non­
functional RET mutations in mice (Jijiwa et al., 2004). Growth retardation of the enteric nervous 
system was observed when the tyrosine residue was replaced with phenyalanine (Jijiwa et al.,
2004). Mice with this mutation either lacked enteric neurons that line the inside of the intestinal 
tract or developed enteric neurons with reduced ganglion cells, but the formation of a small kid­
ney was achieved. Thus proving the signing via Y1062 to be important for embryogenesis of the
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enteric nervous system and development or growth of the kidney (Jijiwa et al., 2004). Further, the 
signaling complex formed via She 1 contributes to the survival of RET in neuroblastoma cells.
The survival properties of SK-N-MC cells were demonstrated in the competitive interaction of 
Sch/ENIGMA and FRS2 to bind to Y1062 (Lundgren et ah, 2006). Thus suggesting cell survival 
properties of RET are specific to cell type and occur in response to the competitive binding of 
different Src adaptor to the tyrosine residue (Lundgren et ah, 2006).
Finally, the tyrosine residue, Y1096, is specific to only one of the RET isoforms, RET 51. The 
phosphotyrosine Y1096 binds to Grb2, which leads to recruitment of Gabl or Gab2 to activate 
the PI3K/Akt pathway (Liu et ah, 1996). Alternatively, Y1096 may recruit Ceasitas B-lineage 
Lymphoma (CBL) and was shown to be required for ubiquitination and degradation of RET 51 
(Calco et ah, 2013).
TYROSINE KINASE INHIBITORS
The kinase domain, specifically the binding sites and the mechanism by which they regulate 
downstream signaling represents targets for drug discovery. Small-molecule tyrosine kinase in­
hibitors (TKIs) focus on the ATP-binding sites found on the intracellular kinase domain of RTKs 
and inhibit signaling by blocking phosphotransferase activity (Noble et al., 2004). While there is 
no RET-specific inhibitor present, there are multikinase inhibitors that have proven to work 
against RET. For instance, Vandetanib (ZD6474) proved to have potent inhibitory effects against 
the kinase domain of RET although it was originally developed as an epidermal growth factor 
receptor (EGFR) inhibitor. The inhibitor suppressed the secretion of calcitonin in 80 percent of 
the patients with sporadic or familial MTC and the remaining 20 percent were partial responses 
induced by the inhibitor (Carlomagno et al., 2003). Vandetanib binds to RET whether it is in its 
phosphorylated or unphosphorylated state with equal affinity, explaining its inhibitory effects
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against other mutated residues. While some residues have demonstrated resistance towards van- 
detanib, it is to the date the most successful anti-RET inhibitor and was approved for treatment of 
locally and advanced MTC tumors (Wells et ah, 2012). Chow et al., 2007 described Sunitinib 
(SU011248) as a multikinase inhibitor that had successfully transitioned from its molecular design 
to an approved target-therapy as it effectively inhibited advanced RET-mediated renal carcinoma 
during phase II clinical trials.
Other inhibitors have also been identified with anti-RET activity, but have had varying results 
including Cabozantinib (XL-184) Zhang et al., 2010) Sorafenib (BAY 43-9006) (Carlomagno et 
al., 2006) and Motesanib (AMG 706) (Sherman et al., 2007). Other drugs have proven less effec­
tive as a RET inhibitor although described to work against RET-mediated malignancies. For ex­
ample, Imatinib (ST1 571), another multikinase inhibitor was described to block RET-mediated 
MTC tumor growth. In vitro, phosphorylation of the Y1062 was blocked in the presence of Ima­
tinib. RET expression was affected with increased exposure to Imatinib, which lead to a decrease 
in cell growth and thus blocked tumor proliferation (de Groot et al., 2006). The concentration of 
Imatinib used to achieve results in vitro were considered far too elevated to attempt in target-thera­
py of MTC. In agreement, clinical trials of this drug proved to be ineffective, as the patients test­
ed either had stable diseases, reduced doses or stopped treatment because of toxic effects (de 
Groot et al., 2006).
RET DEPENDENT TRANSCRIPTION CANDIDATES 
Sproutyl (Spryl)
Sprouty (Spry) proteins represent a class of ligand-inducible antagonists of the RTK-dependent 
signaling pathways. Members of the Spry family are involved in anti-proliferation activity, inhibi­
tion of migration, favoring of differentiation, and promotion of survival. In Drosophila, Spry
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inhibits FGFR and EGFR signaling during trachea and eye development (Hacohen et al., 1998). 
While it is known that Spry proteins suppress Ras-Erk signaling via RTKs, the exact mechanism 
by which Spry proteins function biochemically is not entirely understood (Mason et al., 2006). 
Specifically, because the method in which Spry proteins interact with components of RTK signal­
ing pathways to induce signaling is unclear. While Spry proteins have been described in the etiol­
ogy of several RTK-mediated diseases and disorders, the present study will focus only on the 
Spryl isoform. Spryl has been described as a negative regulator of GDNF/RET-mediated kid­
ney induction and as a candidate tumor-suppressor gene in MTC, respectively (Basson et al., 
2005; Macia et al., 2012).
Spry was first identified in D. melanogaster while genetically screening for regulators of tracheal and 
eye development (Hacohen et al., 1998). Four mammalian Spry homologs were identified based 
on similarity with the Drosophila Spry sequence. The Spry family includes four family members, 
Spry 1-4, and there are three conserved sequences found across all four Spry proteins, including a 
tyrosine kinase-binding (TKB) binding motif, a serine-rich motif (SRM) and a cysteine-rich do­
main (CRD) (Hacohen et al., 1998). The mammalian Spry proteins are similar to the Drosophila 
Spry in the cysteine rich C-terminus, but differ in the N-terminus. The N-terminus of Spry rep­
resent a conserved sequence that promotes its ability to inhibit signaling (Hanufusa et al., 2002; 
Mason et al., 2006). The Spry genes encode relatively small proteins, approximately 63 Kda in 
Drosophila and 32-34 Kda in mammals (Kim et al., 2004). Tyrosine phosphorylation of Spry 
proteins is specific to the isoform, the growth factor and cell type, suggesting that Spry proteins 
are functionally different (Mason et al., 2006). The expression pattern of mammalian Spry pro­
teins was described in embryonic development as well as in adult tissue, and near fibroblast 
growth factor (FGF) signaling complexes associated with mesenchyme-to-epithelial transition 
(Chambers and Mason, 2000).
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The role of the Spryl has been described in the development of different organs, in particular, 
kidney development and RET-mediated ureteric branching (Gross et al., 2003; Basson 2005). In 
mice, Spryl is expressed in the developing metanephric mesenchyme that later becomes the 
nephron and in the branching UB that later becomes the collecting system in the kidney (Gross et 
al., 2003). In addition to RET and GFRal, several other genes such as Wntl 1 are co-expressed 
specifically in the UB tips (Kispert et al., 1996). Spryl behaves as a negative regulator of ureteric 
branching in kidney development via GDNF/RET/W ntl 1 in the Ras-Erk/MAPK pathway (Bas­
son et al., 2005). Basson et al. showed that mice with non-functional Spryl have multiplexed dys- 
plastic kidneys with enlarged ureters and numerous UBs branching at random site along the WD 
(Basson et al., 2005). This phenotype results from failure of GDNF/RET signaling in the prolif­
erating WD that leads to UB induction. An explanation for the phenotype is that increased RET 
signaling in the absence of Spryl leads to hyper activation of the Ras-Erk/MAPK pathway (Bas­
son et al., 2005).
The opposite phenotype is observed in non-functional RET mutations. Mice with non-functional 
RET fail to develop kidneys during birth. Further, mutated Y1062 in which UB induction is 
blocked by decreased Ras-Erk activity also results in renal agenesis (Basson et al., 2005). An ex­
planation for the phenotype observed is that in stimulated conditions, the Ras-Erk pathway is ac­
tivated, followed by translocation of phosphorylated ERK to the nucleus, where it is activates 
transcription of Spry (Mason et al., 2006). Simultaneously, Spry is translocated to the plasma 
membrane where it is tyrosine phosphorylated by Src kinase activity. In this negative feedback 
mechanism, Spry suppresses the Ras-Erk pathway by inhibiting Ras activity (Gross et al., 2003). 
Loss-of-function mutations of Spryl and RET respectively, are opposite examples of defects to 
the kidneys and urinary tract that are caused from misregulation of the Ras-Erk pathway (Basson 
et al., 2005). The non-functional Spryl and RET phenotypes can be rescued (Rozen et al., 2009),
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mice that lacked Y1062 activity and Spryl demonstrated morphological corrections for the renal 
defects seen in the individual non-functional phenotypes. Since Y1062 is a multi-adaptor docking 
site that can lead to PI3K/Akt and Ras-Erk/MAPK signaling, the morphological correction sug­
gests UB branching may be achieved through RET-mediated signals other than those associated 
with Y 1062.
A common outcome of aberrant expression of RTKs aside from development defects is malig­
nancy. Given the Spry family’s behavior as negative regulators has prompted studies to address 
the role of these proteins in cancer. The expression of Spryl has been shown to be down regulat­
ed in breast cancer, prostate cancer, and cardiovascular diseases with minimal explanation as for 
the mechanism by which Spryl functions. Recently, Macia et al. have proposed Spryl as a candi­
date tumor suppression gene in MTC in a mouse model (Macia et al., 2012). The expression of 
Spryl was traced to the thyroid glands from the embryonic state well into adulthood. Non-func­
tional Spryl leads to calcitonin-producing C-cell hyperplasia, which is the primary reason for 
MTC. However, non-functional Spryl did not lead to MTC, but rather C-cell hyperplasia alone 
(Macia et al., 2012). Additionally, Spryl reduced proliferation of oncogenic RET-expressing cells 
by inducing cellular senescence. Macia et al., suggested that Spry-mediated senescence could ex­
plain the tumor suppression, but the mechanism by which expression of Spryl induces senescence 
is not clear.
Protein Tyrosine Phosphatase Non-receptor Type 11 (PTPN11) (SHP2)
The phosphatase SHP2 is a downstream signaling component of RET whether by GDNF stimu­
lation of the wild type receptor or by RET mutant forms (Kurokawa et al., 2001). However, the 
biochemical function of SHP2 and the signaling components surrounding its activity are not en­
tirely understood. Although the mechanism is not entirely understood, it is believed SHP2 is re-
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lated to Spryl and a transcription factor downstream of RET, ETV4, while the transcriptional 
regulation of the associated signaling partners remain unclear.
The Src homology 2 domain-containing phosphatases (SHPs) are a sub-family of non-receptor 
protein tyrosine phosphatases that are conserved between vertebrates and invertebrates. There 
are two mammalian members SHP1 (encoded by PTPN6) and SHP2 (encoded by PTPN11) and 
both have conserved sequences including two SH2 domains, a protein tyrosine phosphatases 
(PTP) domain, a C-terminal tail with tyrosyl phosphorylations sites and a proline rich motif (Neel 
et ah, 2003). The PTK phosphorylation and PTP dephosphorylation represent a signaling motif 
of RTKs. Under normal conditions, SHP2 has low catalytic activity because the SH2 domain 
and PTP domain keep it auto-inhibited. The auto-inhibition is released when the SH2 domain 
binds to a phosphotyrosine on the activated receptor or scaffolding proteins. SHP2 is ubiquitously 
expressed and functions as a signaling component of RTKs by promoting activation rather than 
down-regulation of signaling pathways. Mutations in PTPN11 results in Noonan, LEOPARDS 
syndrome and leukemia. Non-functional SHP2 mutations results in early embryonic defects in 
mice. Neel et al., 2003 has shown SHP2 is important for the development of the central nervous 
system and neural crest cells.
Recent studies suggest that SHP2 promotes the activation of Ras in the Erk/MAPK pathway. 
PTPs are thought to play opposing roles of PTKs in signal transaction and assumed to be nega­
tive regulators. While phosphatase activity is needed for SHP2 to promote activation of the 
pathway, the exact dephosphorylation targets are not clear. In a proposed method, SHP2 com­
petes with Spry land FRS2 adaptor proteins for binding to the Grb2-SOS signaling complex on 
Y1062 to promote Erk/MAPK activation (Hanafusa et ah, 2004). Another study suggests SHP2 
promotes the Ras-Erk/MAPK signaling pathway by inactivating phosphorylation sites on Spryl
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(Jarvis et al., 2006). It has also been concluded that SHP2 acts downstream of GDNF/RET-me- 
diated signaling in branching morphogenesis during kidney development.
Incoranato et al., studied the interactions between mutant RET and the two phosphatases, SHP1 
and SHP2, in the rat phenochromocytoma cell line, PC 12 cells (Incoranato et al., 2004). The 
RET mutations studied included cysteine residue 634 and methionine residue 918 causing MEN 
2A and MEN 2B, respectively. It was concluded the complexes formed by SHP2 and the mutant 
RET were found outside the lipid rafts (Incoranato et al., 2004). Hereby concluding the SHP2- 
mediated signaling occurs outside the raft compartment.
In mice, non-functional SHP2 produces a phenotype similar to that of non-functional RET muta­
tions in which there is reduced UB branching and reduced kidney size. In situ hybridization on 
sections of the kidney showed down regulation of RET target proteins including Wntl 1 and tran­
scription factor ETV4 (Willecke et al., 2011). Studies have shown ETV4 signals are essential for 
RET signaling, but are down regulated in nonfunctional SHP2 mice which may occur via the 
PI3K/Akt pathway (Besset et al., 2000). The development of the kidneys was then observed in an 
organ culture. The reduced UB branching phenotype on the explant remained the same even 
after GDNF stimulation. In agreement with other studies, ERK/MAPK signaling was reduced in 
the UB bud tips of the mutated explants (Willecke et al., 2011). Lack of SHP2 in the UB prevents 
mice with non-functional Spryl from developing numerous UB induction sites. In summary, 
SHP2 may act downstream of Spryl in the GDNF/RET signaling pathway (Willecke et al.,
2011).
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ETS Translocation Factor Variant 4 (ETV4)
Several genes described to be important during kidney development are downstream regulators of 
the G D N F/G FR al/R ET signaling pathway. Recently, Fu et ah, described the role of overlap­
ping ETV4 and ETV5 in the developing mammalian kidney, specifically in the UB tips during 
branching morphogenesis (Fu et ah, 2009). ETV4 and ETV5 are co-expressed during kidney 
formation in a similar pattern as RET in the Wolffian duct, UB outgrowth and UB tips. In mice, 
nonfunctional Etv4 and non-functional ETV5, together, result in phenotypes similar to the non­
functional RET phenotypes. Additionally, those phenotype resemble the nonfunctional SHP2 
phenotypes (Willecke et al., 2011). That is, the absence of both Etv4 alleles and a single Etv5 al­
lele displayed renal agenesis whereas mice with a variation of the mutation displayed different 
degrees of kidney reduction and UB branching (Fu et al., 2009). Further analysis demonstrated 
the PI3K/Akt pathway important for ETV4 and ETV5 expression in UB tips whereas the Ras- 
Erk/MAPK and PLG pathways did not affect the expression of these genes.
There are 28 human ETS genes and their homologues are found across vertebrates and inverte­
brates. The polyomavirus enhancer activator 3 (PEA3) subfamily of ETS transcription factors 
consists of three members ETV1 (Ews), ETV4 (Pea3) and ETV5 (Erm). The defining characteris­
tic of the encoded proteins is the ETS domain that has three conserved a  helices, and four an­
tiparallel [3-sheets. The ETS domain DNA binding motif is approximately 85 amino acids long 
and binds to DNA sequences with a 5 -GGA(A/T)-3' (Sharrocks et al., 2001). There is specula­
tion about the way in which the ETS transcription factors regulate gene expression of specific 
genes as they all potentially bind to the same DNA target. Possible reasons include tissue or cell- 
type specificity, the sequence surrounding the 5 -GGA(A/T)-3' sequence or the ability of the 
transcription factors that bind in close proximity to the ETS proteins (Oh et al., 2012). Expres­
sion of ETV1, ETV4 and ETV5 has been traced in the development of numerous organs from
Page 32 of 85
the embryonic stages well into adulthood. The expression of two closely related genes, ETV4 and 
ETV5, has been seen in the branching morphogenesis of organs including the lung, mammary 
gland, salivary gland and the UB of the developing kidney (Chotteau-Lelievre, et al., 2003). The 
co-expression of these two genes has been demonstrated to be essential in neuronal, spermatago- 
nial and limb development (Oh et al., 2012). ETV4 was identified as a GDNF-RET target in mo­
tor neurons during limb development in the chicken (Hasse et al., 2002). It was shown that 
GDNF induces expression of ETV4, but only in a restricted subset of cervical motor neurons 
showing the spatial restriction of ETV4 response (Hasse et al., 2002).
While many proteins associated with the RET signaling pathway have been identified and dis­
cussed in the context of developmental biology, the transcriptional changes induced by the wild 
type receptor, particularly with respect to these signaling proteins in neuroblastoma cells, is less 
clear. The molecular mechanism(s) that connects the mutations or mutated sites on the receptor 
to the disease phenotypes are not entirely understood, in part, because the transcriptional changes 
of the putative signaling proteins involved in the proposed mechanistic pathways remain elusive. 
Analyzing the expression levels of each gene using real-time quantitative PCR in response to the 
activation of RET, will aid in elucidating RET-mediated mechanisms that contribute to these dis­
eases, and understanding the role of RET on downstream signaling and cellular function. In the 
present study, the gene expression of Spryl, SHP2 and ETV4 in response to the activated wild 
type receptor RET is presented.
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MATERIALS and METHODS
Primer Design
All primers were designed based on published genomic sequences obtained from NCBI Genebank 
or published papers using Primer-Blast. The primers are listed as three candidate genes followed 
by two housekeeping genes.
Gene name: (Spryl) Sprouty homolog 1 
NCBI accession number: NM_001258038 
forward primer, 5-ACATGGCAGTGGCAGTTCGT-3 
reverse primer, 5-GTCTTGGTGCTGTCCGAGGAG-3 
Amplicon size (bp) 194
Gene name: (Shp2) Tyrosine-protein phosphatase non-receptor type 11
NCBI accession number: NM_002834
forward primer 5-CCGGACAGGGACGTTCATTG-3
reverse primer: 5-GCTTGTGTCTGGACCATCCC-3
Amplicon size (bp) 135
The primers for Etv4 were designed according to (Pellecchia et al., 2012).
Gene name: (Etv4) ETS translocation variant 4 
NCBI accession number: NM_()01986.2 
forward primer 5-GCTCGCTGAAGCTCAGGT-3 
reverse primer 5-TCCTTCTTGATCCTGGTGGT-3 
Amplicon size (bp) 112
The housekeeping genes GAPDH and f-l-Actin were designed according to (Sikand et ah, 2012). 
Gene name: (GAPDH) Glyceraldehyde 3-phosphate dehydrogenase
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NCBI accession number:
forward primer 5-ACCCACTGCTGCACGTTTGAC-3 
reverse primer 5-TGTTGCTGTAGCCAAATTCGTT-3 
Amplicon size (bp) 100
Gene name: (Actb) [i-Actin 
NCBI accession number:
forward primer 5-GCCGGGACCTGACTGACTAC-3 
reverse primer 5-TTCTCCTTAATGTCACGCACGAT-3 
Amplicon size (bp) 100
Cell Culture
Human neuroblastoma cell line SK-N-SH [American Type Culture Collection (ATCC 
#HTB-11)] and were cultured in EMEM supplemented with 10% FBS according to manufactur­
er’s recommendations. All cells were maintained at an atmosphere of 37°C with 2% relative hu­
midity and 5% CO 2. Cells were passed from T-125 flasks to 6 well plates at a concentration of le6 
cells/well and grown overnight. The plates were then aspirated, rinsed with PBS, and starved in 
serum free medium at 2 hours. Following the serum starvation, the cells were treated with serum 
free medium containing the GDNF growth factor (Promega, cat. No. #G2781). The GDNF 
treatment was diluted to final concentrations of lng/mL or 0. lng/m L in serum free media for 
subsequent experiments. Cells were collected at 0 hours, 2 hours, 4 hours, 6 hours, 8 hours and 
12 hours, and harvested for RNA extraction at the end of each time interval tested. RNA was 
extracted using a Trizol-based method. Total RNA was resuspended in sterile DEPC treated 
water and quantitated by O D 260. The final concentration of the RNA was diluted prior to 
being stored at -80°C.
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Reverse Transcription cDJVA synthesis
Extracted total RNA was subjected to reverse transcription prior to polymerase chain reaction in 
the two-step protocol. The reverse transcriptase reaction was performed using oligo(dT) primers 
obtained from Invitrogen Life Technologies. In brief, a 20 pL reaction was set up using 10 pL of 
sterile DEPC treated H 2O, 1 pL of oligodT primers, 1 pL of 2.5mM deoxynucleotide triphosphate 
dNTP mix, 1 pL of total RNA. The reactions were dispensed in 8 -strip PCR tubes and sealed 
with domed caps and amplification was carried out using Applied Biosystems Veriti Thermal Cy­
cler using the following conditions: 60°C for 3 minutes followed by 4°C for 1 minute. The reac­
tion was paused and the remaining reagents were added to the reaction, 4 pL of Invitrogen 5X 
Buffer, 2 pL of Invitrogen DTT, 1 pL of Invitrogen RNAase OUTand 1 pL of Invitrogen Super- 
Script II Reverse Transcriptase and cDNA synthesis continued under the following conditions: 
42°C 30 minutes, 70°C 5 minutes. The sequence specific lyophilized primers obtained from Invit­
rogen were diluted in autoclaved H2O to make lOOpM stock solutions, which were then diluted in 
autoclaved H 2O to make 1 OpM working solutions. The reverse transcriptase reaction was per­
formed according to the conditions described in the previous section. Unlike the primer oligo(dT) 
reaction, the sequence specific reaction only requires a reverse 3’ primer for cDNA synthesis.
Standard Polymerase Chain Reaction (PCR)
The PCR reactions were prepped using reagents obtained from Invitrogen and Sigma-Aldrich. In 
brief, a 25 pL reaction was set up containing: 15 pL nucleated free PCR grade autoclaved H 2O, 1 
pL of 2.5mM deoxynucleotide triphosphate dNTP mix, 1 pL of 10 pM sequence specific forward 
and reverse primers obtained from Invitrogen, 5 pL Sigma 10X PCR Buffer, 1.5 pL of 1.5mM 
Sigma MgCb, 1 pL of cDNA template and 0.5 pL. of 5 U/pL Sigma Taq Polymerase. The reac­
tions were dispensed in 8 -strip PCR tubes and sealed with domed caps and amplification was car­
ried out using Applied Biosystems Veriti Thermal Cycler using the following conditions: 1 cycle of
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95°C for 5 minutes, followed by 40 cycles of 95°C for 30 seconds, 58°C for 30 seconds, and 72°C 
for 1 minute, followed by 1 cycle of 72°G for 7 minutes. The experiments included ‘no reverse 
transcriptase’ and ‘no template’ controls. The PCR conditions were then altered to 1 cycle of 
95°C for 2 minutes, followed by 35 cycles of 95°C for 15 seconds, 55°C for 15 seconds, and 6 8 °C 
for 45 seconds, followed by 1 cycle of 6 8 °C for 5 minutes. The annealing temperature was altered 
to the melting temperature of each gene, respectively.
Gel Electrophoresis
1% and 1.5% agarose gels were used for the gel electrophoreses reactions. The gels were pre­
pared with lg or 1.5g agarose into lOOmL of the respective buffer used in the experiment either 
IX TAE or IX TBE which were diluted from 50X TAE or 10X TBE stock solutions, respectively. 
The components of the buffers included: (TAE) Tris Base, Glacial Acetic Acid, Na2 EDTA, pH 
~8.5; (TBE) Tris Base, Boric Acid and 0.5M EDTA, pH ~8.0. The running buffer used in the 
reactions were the buffer used to make the gel and stained with ethidium bromide (EtBr). 10 pL 
of the PCR product were diluted with 3 pL of DNA Loading Dye, 10 pL of the mixture were 
loaded in each respective well on the gel. The gel ran for approximately 45 minutes at 100 volts. 
Results were analyzed using the Launch TS Software on the UVP Ultraviolet Gel Imaging Sys­
tem.
Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)
Two different approaches were employed for qRT-PCR, SYBR and TaqMan assays. The real­
time PCR reactions were prepped using Brilliant SYBR Green Master Mix including ROX pas­
sive reference dye obtained from Applied Biosystems. In brief, a 25 pL reaction was set up con­
taining 12.5 pL of 2X SYBR Green PCR Master Mix, 1.5 pL of 10 pM of each of the sequence 
specific forward and reverse primers, 1 pL of 1 in 5 diluted template cDNA synthesized from
Page 37 of 85
RNA extracted from SK-N-SH treated neuroblastoma cells, and 9.5 pL of nucleated free PCR 
grade H 2O. The reactions were dispensed in qPCR 8-strip flat-capped tubes and amplification 
was carried out using Applied Biosystems StepOne Plus Real-Time PCR System using the follow­
ing conditions: 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. The experiment included a ‘no reverse transcriptase’ control. Otherwise, the real-time 
qPCR reactions were set up using Taqman RNA-to-Ct 1 -Step Kit obtained from Applied Biosys­
tems with 900nM primers (forward and reverse) and 250nM probe. In brief, a 10 pL reaction was 
set up containing 5 pL of TaqMan RT-PCR 2X, 3 pL of sterile DEPC treated H2O, 0.5 pL of 
20X Taqman Gene Expression Assay for each respective gene being tested, 0.5 pL of RT Taq­
man Enzyme diluted to 20X and 1 pL of 1 in 10 diluted lOOng/mL RNA template. The reac­
tions were dispensed into 96-well optical plates and sealed with Applied Biosystems sealing tape 
and amplification was carried out using Applied Biosystems StepOne Plus Real-Time PCR Sys­
tem using the following conditions: 48°C for 15 minutes, 95°C for 10 minutes, followed by 40 cy­
cles of 95°C for 15 seconds and 60°C for 1 minute. Three technical replicates were performed 
per RNA sample along with a ‘no template’ control. Specificity and amplification were confirmed 
by running the samples on a 1 % agarose gel. Gene expression was quantified by using the relative 
standard curve method and AACt Livak method. Expression of Spryl, Shp2 and Etv4 were 
normalized to either p-Actin or GAPDH expression, relative to treatment. The treatments in­
cluded, serum-free (untreated) control, 4-hour serum treatment and 4-hour 100 ng/mL GDNF 
treatment. Ten-fold serial dilutions of lOOng/mL RNA were used to construct a standard curve, 
including, (IX, 0. IX and 0.0IX ). The mean and ± standard deviation of the candidate genes 
normalized to the housekeeping, endogenous controls were calculated from four independent ex­
periments.
The TaqMan Gene Expression Assays used are listed below:
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Gene Name sprouty homolog 1, antagonist of FGF signaling (Spryl) 
NCBI Location Chromosome Chr.4: 124317956 - 124324910 
NCBI Accession no. NM_001258038.1 Amplicon Length 103 
Dye Label and Assay Concentration: FAM-MGB /  20X
Gene Name: protein tyrosine phosphatase, non-receptor type 1 l(Ptpnl 1)
NCBI Location Chromosome Chr.12: 1 12856536 - 112947717 
NCBI Accession no. NM_002834.3 Amplicon Length 78 
Dye Label and Assay Concentration: FAM-MGB /  20X
Gene Name ets variant 4 (Etv4)
NCBI Location Chromosome Chr. 17: 41605211 - 41623762 
NCBI Accession no. NM_001079675 Amplicon Length 70 
Dye Label and Assay Concentration: FAM-MGB /  20X
Gene Name: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Endogenous Control 
(probe, non-primer limited)
NCBI Accession no. NM_002046.3 Amplicon Length 122 
Dye Label and Assay Concentration: FAM-MGB /  20X
Gene Symbol: (3-actin (Actb) Endogenous Control 
NCBI Location Chromosome Chr.7: 5566779 - 5570232 
NCBI Accession no. NM_001101.3 Amplicon Length 63 
Dye Label and Assay Concentration: FAM-MGB /  20X
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RESULTS
PRIMER DESIGN of CANDIDATE GENES
In order to evaluate expression changes of specific genes in response to RET activation, RT-PCR 
and real-time PGR were performed. Primer design is an essential application component for re­
verse transcription polymerase chain reaction (RT-PCR) in order to yield successful amplification 
of a target sequence. The reaction requires two PGR primers that are specific for the sequence 
amplified. When measuring gene expression it is also important for the primers to differentiate 
between cDNA and genomic DNA amplification. The forward and reverse primers designed for 
Spry 1 span a single exon in the mRNA sequence (figure no.3). The forward Shp2 primer was 
designed to span an exon junction while the reverse primer lies within a single exon to reduce the 
risk of false positives from amplifying genomic DNA (figure no.3). Theses primers will anneal to 
cDNA from spliced mRNAs, but not to genomic DNA. Likewise, the forward primer designed for 
Etv4 spans an exon junction, while the reverse primer spans a different exon (Pellecchia et al.,
2012). The primers for target and reference genes were designed using Primer-Blast to have simi­
lar properties so that they could be tested simultaneously in subsequent reactions. The primers for 
(3-actin and GAPDH, were designed according to the primer sequences used for real-time QPCR 
by (Sikand et al., 2012) (figure no.4). Both forward and reverse f.Uactin primers were designed 
within a single exon. The forward and reverse GAPDH primers flank a region that contains an 
intron towards the end of the mRNA sequence. The GAPDH primers were designed to bind to 
different exons to promote amplification of cDNA such that genomic DNA contamination is 
avoided. The PCR product amplified from the region of cDNA excluding introns, will be smaller 
in size compared to a region containing introns. Thus, amplification of contaminating genomic 
DNA should be eliminated.
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PRIMER CHARACTERIZATION of CANDIDATE GENES
Extracted total RNA (work by a different graduate student from the lab) was subjected to reverse 
transcription followed by polymerase chain reaction in order to determine the specificity of the 
primers designed. The synthesis of DNA from an RNA template, via reverse transcription, pro­
duces complementary DNA, termed cDNA. The reaction requires an RNA template and a short 
primer complementary to the 3’ end of the RNA sequence to direct the synthesis of the first 
strand of cDNA. The cDNA template is then used for the polymerase chain reaction to exponen­
tially amplify the target DNA sequence. The PCR product is then evaluated by gel electrophore­
sis. In this method, an electrical field is applied such that the PCR product travels through the 
gel, from negative end to the positive end, at a speed that is inversely proportional to the size of 
the molecule. Thus, smaller fragments travel quicker than larger fragments.
The reverse transcription reaction was originally performed with oligo(dT) primers to synthesize 
cDNA from the total RNA extracted from SK-N-SH Ing/mL GDNF-treated neuroblastoma 
cells. While some genomic DNA contamination is possible, the purity of the total RNA is critical 
in order to capitalize on the sensitivity of the technique. The purity of the starting total RNA 
template was 1.64 A 2 6 O / 2 8 O . Oligo(dT) primers are nonspecific primers that offer flexibly of the 
cDNA so that the cDNA, in a two-step reaction, may be used as template for subsequent poly­
merase chain reactions with gene-specific primers, for genes in the present study. Oligo(dT) 
primers initiate reverse transcription at the 3’ polyA tail of the transcript, but do not ensure that 
the 5’ end of long mRNAs is converted to cDNA. In that case, a different priming method, ran­
dom primers could be used to increase the probability that the 5’ mRNAs convert to cDNA, re­
sulting in shorter cDNA fragments across the mRNA sequence. Transcriptase activity depends in 
part, on the purity and integrity of the starting material, but also by secondary structures, which
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can obstruct the reverse transcriptase activity and lead to incomplete cDNA synthesis. The tem­
perature of the reaction is equally as important for proper cDNA synthesis.
The primers for GAPDH and (3-actin were subjected to reverse transcription with oligo(dT) 
primers followed by polymerase chain reaction as shown in (figure no. 5). The DNA ladder in the 
first lane represents a marker of known DNA fragment sizes ranging from 0.1 base pairs (bp) to 10 
kilo bases (kb). In the initial experiment, none of the experimental samples, including the ‘no re­
verse transcriptase’ and ‘no template’ controls, showed any amplification (figure no.5). Therefore, 
the use of oligo(dT) primers for reverse transcription proved to be ineffective as they did not lead 
to the amplification of Gapdh and j3-actin. The lack of PCR product can be explained by poor 
quality of PGR template, primer design or the reagents used in the reaction.
Sequence-specific primers can provide high specificity but the cDNA synthesized can only be used 
to study the particular gene for which the primers were designed, unlike oligo(dT) primer depen­
dent reverse transcription which can be used to study many possible genes. Gene-specific primers 
were used in subsequent reactions to improve data analysis. In figure no. 6, lane 2, GAPDH am­
plification was observed. Unfortunately, amplification was also seen in the ‘no reverse transcrip­
tase’ and ‘no template’ control (lanes 3 and 4, respectively), suggesting that the amplification was 
not mRNA specific. However, when amplifying for (3-actin, a much more specific signal was ob- 
tainined. While the intensity of the band is high and no distinct, lane 6 represents amplification 
of (3-actin. The negative control reactions represented in lanes 7 to 9, suggest there is no genomic 
DNA amplification or genomic DNA contamination in the sample. To confirm the amplification 
of (3-actin was the correct size, 100 bp, subsequent experiments used 1.5% agarose gels. A higher 
gel percentage has smaller pores, which, in turn, allow for more clear measurements of small 
fragments.
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The specificity of the (3-actin primers was confirmed by single distinct bands present in lanes 2 
and 5 (figure no. 7). This was accomplished by diluting the RNA template used in the reverse 
transcription reaction to 1 in 10 diluted 100ng/mL and 1 in 5 diluted lOOng/mL. Seocnd, de­
creasing the Taq polymerase volume froml pL in a 25 pL reaction to 0.5 pL. Lastly, the final 
primer concentration was set to 0.6 pM per 25 pL reaction volume. The Taq polymerase and 
final primer concentration modifications were maintained in subsequent experiments. The speci­
ficity of Etv4 and Spryl primers were confirmed by distinct bands present in lanes 2 and 4, re­
spectively (figure no. 8). The inclusion of (3-actin in this experiment served as a positive control. 
Amplification of the genes were present in the ‘+ reverse transcriptase’ controls, but not in the ‘no 
reverse transcriptase’ controls. The two separate experiments show the intensity of the band is 
dependent, in part, on the concentration of RNA template used in the reverse transcription reac­
tion.
|3-actin were subjected to reverse transcription with oligo(dT) primers in order to determine if the 
modifications made to the reaction components would yield cDNA synthesis using oligo(dT) 
primers. (3-actin was chosen as it maintained positive results in the experiments thus far. Figure 
no.9 shows amplification of (3-actin with sequence-specific primers and oligo(dT) primers in lanes 
2 and 6, respectively. Reverse transcription reactions were tested using oligo(dT) primers followed 
by polymerase chain reaction with other sequence specific primers, but the results were not repro­
ducible (data not shown).
The specificity of Shp2 was confirmed by the band present in lane 8 (figure no. 10). In this exper­
iment (3-actin and GAPDH served as controls. The inclusion of Etv4 in this experiment owed to 
the PCR product smear present in lane 4 in figure no.8. Smearing can be can caused by too 
much starting template evident in the (left) undiluted RNA experiment, which was corrected by
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the (right) 1 in 5 diluted lOOng/mL RNA template (figure no.8). Also, because suboptimal primer 
concentrations can affect band quality, the final concentration of the primers in this experiment 
were set to 0.4 pM. The number of cycles during the polymerase chain reaction were also re­
duced from 40 to 35. The agarose gel was stained with EtBr overnight and visualized the follow­
ing morning, but there was no amplification of Etv4 seen in lane 4 (figure no. 10).
Subsequent experiments were performed to confirm the specificity of the primers for the appro­
priate sequences. The experiments continued to use the following final concentrations: 0.6 pM 
forward and reverse primer, lU/25pL Taq polymerase, 0.125 mM dNTPs, 1.5mM MgCl2+,in­
cluded 35 cycles during polymerase chain reaction. The reverse transcription reactions was per­
formed with sequence-specific reverse primers and 1 in 5 diluted 100ng/mL RNA templates, all 
of which proved successful in preceding experiments. Such conditions were used in combination 
with increasing annealing temperature to avoid primer dimers or unspecific DNA binding. How­
ever, distinct amplification of the genes were achieved in inconsistent patterns (figure no. 11), re­
gardless of the optimization method and thermal cycler conditions used.
TRANSCRIPTIONAL PROFILING of CANDIDATE GENES
Because of the difficulties in obtaining reproducible results using standard RT-PCR subsequent 
experiments used real-time PCR. Real-time quantitative polymerase chain reaction, also referred 
to as real-time PCR, or qPCR, provides a method for determining the amount of a target se­
quence present within in a sample. The reaction is characterized by the point at which amplifica­
tion of the target sequence achieves a significant level of fluorescence as the reaction progresses, 
thus, in real time, rather than by end-point analysis as in standard PCR. Irrespective of the real­
time PCR method used, the data is read as the number of PCR cycles necessary to achieve ampli­
fication that is detected by florescence signals. The amplification curve can be divided into four
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parts, the baseline, the exponential phase, the linear phase and the plateau phase. The baseline 
refers to the earlier cycles where there is no significant change in fluorescence signal. The thresh­
old is set above the baseline in the linear phase, but sufficiently low to be within the exponential 
phase of the amplification curve. The accumulation of fluorescence becomes significantly greater 
compared to the baseline during the exponential phase. The relative measure of the concentra­
tion of the template in the PGR reaction is read as the intersection between the amplification 
curve and the threshold value. This is termed cycle threshold (Gt) value.
Quantification may either be absolute or relative depending on the experimental goals. In the 
present study, relative quantification was used to compare changes in gene expression, to deter­
mine the fold-difference in expression. This method requires normalization of fluorescence sig­
nals for the target being tested against an endogenous control. An endogenous control is a refer­
ence gene that should be expressed at similar levels in all samples tested. Housekeeping genes can 
be used as endogenous controls as they are involved in basic cellular functions and assumed to be 
constitutively expressed regardless of treatment.
In a two-step reaction (figure no. 13), cDNA was first synthesized with sequence-specific primers 
and then subjected to real-time PCR using the SYBR Green method. SYBR green binds to the 
double stranded DNA by intercalating between adjacent base pairs. This method quantifies 
cDNA, reverse transcribed from RNA, by measuring the florescence signal emitted by the SYBR 
green dye at the end of each cycle bound to double stranded DNA (Wittwer et al., 1997). While 
quantification of (3-actin and Spryl was obtained, Spryl did not yield expected results. The Ct 
value for the ‘+ reverse transcriptase’ reaction did not register above background and amplifica­
tion of Spryl was not detected. Instead, amplification was detected in the ‘no reverse transcrip­
tase’ reaction probably owing to recognition of nonspecific double stranded DNA. SYBR Green
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experiments were continued with different annealing temperature, primer concentrations and 
cDNA dilutions (data not shown), but proved to be unsuccessful.
To improve gene expression data analysis, a different real-time PCR method was employed using 
the TaqMan method. TaqMan real-time PCR uses specific primers to quantify cDNA, where 5’- 
3’ exonuclease activity of Taq DNA polymerase degrades 5’ fluorophore group of the probe and 
the florescence emitted is measured at the end of each cycle during exponential stages of the PCR 
reaction (Livak et al., 1995). The probe contains a fluorescent FAM dye, termed a fluorophore, 
on the 5’ end and a minor groove binder (MGB) quencher molecule on the 3’ end. The proximity 
of the quencher molecule to the fluorophore keeps it from fluorescing due to fluorescent reso­
nance energy transfer (FRET) (Livak et al., 1995). In the presence of the template, the probe 
bind downstream of the forward primer and during the extension phase of PCR is removed by 
the 5’ nuclease activity of Taq polymerase. When the probe is removed, the fluorophore and 
quencher are separated allowing the fluorescence signal to be detected as the quencher no longer 
inhibits its activity. This continues at each cycle during the reaction and the accumulation of sig­
nal emitted from the fluorophore is proportional to the amount of template present in the sample.
The previously designed sequence-specific primers were not used for the Taqman real-time PCR 
reactions. Instead, predesigned primer and probe gene expression assays were selected. The real­
time PCR reaction was performed as a one-step reaction in which the reverse transcription and 
polymerase chain reaction were carried out consecutively in a single reaction tube. The real-time 
PCR reactions were performed using technical replicates where the template used derived from 
the same SK-N-SH RNA extraction. Three replicates were used to control for validity of the 
method. The bar height indicates the average expression and ± standard deviations of the genes 
in response to the experimental conditions: untreated (serum-free), 4hr serum treatment and 4hr
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GDNF treatment, respectively (figure no. 14). The data is presented as the average Ct value which 
denotes the cycle at which fluorescence signal, indicative of the template present, was first signifi­
cantly greater compared to the baseline.
GAPDH and (3-actin represent the endogenous controls in the present study. While the average 
Ct values are consistent for GAPDH across the treatments (22.95, 22.48, 22.10), they are not for 
(3-actin (30.55, 27.15, 30.21). In the target genes, the average Ct for serum is lower and the aver­
age Ct for GDNF is higher relative to the untreated (serum-free) control. While the resultant av­
erages are graphed similarly for Spryl and Etv4, they are different for Shp2. The gene expression 
of the housekeeping genes were compared by calculating the A in Ct average. The value is ex­
pressed as the average Ct of the housekeeping gene subtracted from the average Ct of the target 
gene. There is great disparity in the A in Ct average compared between the two housekeeping 
genes (figure no. 14). When compared to (3-actin, Etv4 and Shp2 appear to have negative values 
and Spryl has positive values. When compared to GAPDH, the A in Ct average results in posi­
tive values for all of the genes.
Relative quantification requires a standard curve to compare the expression levels of a gene in a 
treated sample versus an untreated sample. The untreated (serum-free) control was a reference 
sample used as basis for relative quantification results. The template used to construct the three- 
point standard curve was RNA extracted from SK-N-SH untreated (serum-free) neuroblastoma 
cells. The cDNA reverse transcribed from RNA is expected to express both the target gene and 
the housekeeping gene. Standard curves were plotted to known concentrations and then created 
by performing real-time PCR on serial dilutions of the template. The highest concentration was 
undiluted lOOng/mL RNA plotted as (IX) on the standard curve. When the initial concentration 
of the template is high (IX), the Ct is reached at an earlier amplification cycle. The second con-
Page 47 of 85
centration was 1 in 10 diluted lOOng/mL RNA plotted as (0. IX) on the standard curve. The 
most diluted template to construct the standard curve was 1 in 100 diluted 1 OOng/mL plotted as 
(0.0IX) on the curve. The Ct of the most diluted template is reached at a later amplification cy­
cle. A linear regression of the Ct values derived from the template dilutions are plotted against 
the log of the initial copy number. The regression line is used to determine the concentration of 
the unknown samples from their Ct values relative to the standard. Figures no. 15-18 and 20-23 
represent the standard curves for each gene plotted as grey boxes, respectively.
The results show aberrant fold differences when normalized to J3-actin (figure no. 19). The refer­
ence gene should have stable expression levels in all samples and should not change with treat­
ment. The serum treatment and GDNF treatment were tested using 1 in 10 diluted lOOng/mL 
RNA (0. IX) to ensure the expression level of the template fell within the limits of the standard 
curve, such that the Ct value is between the highest and lowest dilutions on the standard curve. 
The unsuitability of P-actin as an endogenous control is reflected in the efficiency of the assays 
(table no. 1). The efficiency of the assay is determined by the rate at which the PCR product is 
detected and that is measured as a percentage. In table no. 1, the efficiency for [3-actin is well 
above the accepted 110%, suggesting possible pipetting error in serial dilutions or co-amplification 
of nonspecific product and in the second experiment, the efficiency is below 90% indicating sub- 
optimal reaction conditions. The efficiency of an assay is generated from the standard curve. 
Because the replicates were stochastic for all treatment conditions, the normalization to P-actin 
resulted in incorrect relative quantification of gene expression.
A second efficiency measurement is the R2 value. This value indicates how well the value of Y 
(Ct) can be used to accurately predict the value of X (quantity) in a standard curve. The R2 value 
when close to 1 assumes there is a 2-fold difference between each Ct value on the standard curve.
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While the normalization to (3-actin was not considered, Shp2 showed a distinct difference in the in 
response to GDNF treatment (figure no. 17). The earlier Ct values suggest a possible 2-fold upreg- 
ulation of Shp2 in response to the activated RET receptor when compared to the untreated 
(serum-free) control. While these results are interesting they were not reproducible in subsequent 
experiments.
The results show minimal fold differences when normalized to GAPDH (figure no.24). The ex­
pression of GAPDH in response to the three experimental conditions was uniform and the varia­
tion between replicates was minimal (figure no. 20). In table no.2, the efficiency of GAPDH is 
well above 110% in the earlier experiment, but within the acceptable range in latter experiments. 
Because the replicates for each treatment were much less stochastic compared to j3-actin, relative 
quantification of gene expression normalized to GAPDH was made possible.
DISCUSSION
In order to evaluate the transcriptional changes that might occur in genes associated with RET 
dependent signaling, we studied the gene expression of RET-dependent signaling proteins in the 
human SK-N-SH neuroblastoma cell line using real-time PCR. Initially, sequence-specific 
primers were designed using Primer-Blast to amplify the genes Spryl, Shp2 and Etv4. Different 
reverse transcription priming methods including oligo(dT) primers, random primers and se­
quence-specific primers resulted in inconsistent amplification results (figure no. 5-12). While am­
plification of the target genes was achieved with sequence-specific primers, the results were not 
reproducible, despite continued optimization efforts. To improve data analysis real-time PCR was 
performed using the SYBR Green method, but also proved unsuccessful (figure no. 12). To estab­
lish whether the signaling proteins under study were either induced or repressed in response to the 
activation of RET, TaqMan gene expression primer and probe assays were selected. The real-
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time PCR data was analyzed to show the relative changes in gene expression levels using the Livak 
AACt method based on the 2 'AACl equation (Livak and Schmittgen, 2001). Relative quantifica­
tion relates the expression of a gene in a given sample to that of another sample such as an un­
treated control. The correction of experimental variability in a real-time PCR experiment is 
achieved by normalization to an endogenous control, more specifically, a housekeeping gene. 
Housekeeping genes are involved in basic cellular functions and assumed to be constantly ex­
pressed at the same level regardless of treatment; however, the expression of (3-actin did not ex­
hibit those properties (figure no. 15 and table no. 1). Variation in the expression of a housekeeping 
gene can potentially mask the changes in expression of the target gene(s). Further, recent studies 
have shown expression of the commonly used housekeeping genes including 18S RNA, GAPDH, 
and (3-actin to vary under diverse conditions (Dheda et al., 2005). The unsuitably of (3-actin as an 
endogenous control in the real-time PCR experiments resulted in normalizing gene expression 
levels to GAPDH.
The gene expression normalized to Gapdh showed discrete fold differences, less than two-fold, in 
response to the activated RET receptor when treated with GDNF for 4 hours (figure no 24). The 
biological significance of a given-fold change is likely to depend on the gene and on the experi­
mental context. A two-fold differential is a relatively small change, but considered functionally 
significant in the development of the mammalian kidneys. The changes in gene expression lead 
to functionally significant changes in the protein that cause profound developmental effects in the 
kidney. The expression of Etv4 is upregulated by a 2.9-fold in response to GDNF-RET signaling 
during kidney development and is essential for ureteric bud branching morphogenesis (Lu et al., 
2009). While the expression levels in that experiment were accessed via Affymetrix microarray 
analysis, minimal fold difference of 0.24 and 0.61 were observed in neuroblastoma cells using 
real-time PCR (Table no.2). Although direct comparison between real-time PCR reactions can-
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not be made, an average fold change of 0.42 is a small numeric value, indication of a weak re­
sponse to 4-hour GDNF stimulation.
The expression of Spryl is upregulated by a 3.3-fold in response to GDNF-RET signaling in the 
ureteric bud (Lu et al., 2009). However, those changes were not observed in neuroblastoma cells. 
When normalized to (3-actin the fold difference ranged from 0.15 to 1.50 (figure no. 19) and when 
normalized to GAPDH the fold difference ranged from 0.11 to 1.52 (figure no.24). The fold dif­
ference is so small that functionally, it may be considered unimportant. One explanation for the 
minimal change in gene expression is the use of the human SK-N-SH neuroblastoma cell line, as 
there are genes that are only expressed transiently or only in certain tissues. In addition, the SK- 
N-SH cells are a differentiated cell line and the developmental activity of the genes of interest, 
Spryl, Shp2 and Etv4, were described early stages of kidney development. While neuronal and 
kidney systems derived from neural crest cells and differentiate similarly, neuronal systems may 
behave differently from kidney systems.
Further, transcription of these genes may not be dependent on RET activation alone, but rather 
in combination with other ligands. It has been established that the SK-N-SH neuroblastoma cell 
lines expresses RET, but different cell types express characteristic sets of transcriptional regulators. 
Neuroblastoma cells have demonstrated to require TGF-P for GDNF expression in the RET sig­
naling pathway as the GDNF family of proteins form a subdivision of the transforming growth 
factor (3 (TGF-P ) superfamily (Mason, Ivor, 2000). The co-expression, of a ligand other than 
GDNF may be necessary for gene expression of these signaling proteins. And because different 
cell types often respond in different ways to the same extracellular signal.
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The Ct value in real-time PCR is a dependent variable affected by treatment and concentration 
of template. The Ct values become less efficient at high dilutions because they are more sto­
chastic in the presence of less template. While the template may have not presented an issue, it 
seems likely that the time-course of GDNF stimulation would elicit a more signifiant change in 
gene expression. Perhaps the Spryl, Shp2 and Etv4 genes are not expressed transiently or rapidly 
in response to RET-GDNF signaling, but rather by late responses to longer stimulation with 
GDNF. More time points, other that the 4-hour GDNF stimulation, are needed to elicit elevated 
gene expression responses. Longer GDNF stimulation, such as 6-hour, 8-hour, 12-hour treatment 
may promote transcription of the genes. Alternatively, in stimulated conditions, the RET recep­
tor exists in a phosphorylated state, but the magnitude of the signal is not sufficient to transduce 
the signal to the nucleus so that target proteins, including transcription factors, may be activated 
to change patterns in gene expression.
The lack of biological replicates could have also contributed to the minimal changes in gene ex­
pression observed. The use of technical replicates provided a limitation in this study as the data 
represents a single group of RNA that was extracted from SK-N-SH neuroblastoma cells, there­
fore the biological material analyzed is the same. The findings from these experiments only repre­
sent that specific RNA extraction and measure the reproducibility of the results. To draw mean­
ingful conclusions, independent biological replicates are needed. Biological samples in which dif­
ferent RNA extractions from different SK-N-SH neuroblastoma cell cultures were stimulated with 
GDNF and then subjected to real-time PCR for relative gene expression analysis. The findings 
from such experiments would show similar patterns of gene expression and how those expression 
patterns are differ between untreated (serum-free), 4-hour serum and 4-hour GDNF treatments.
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CONCLUSION
Because it has been proposed Etv4 may act downstream of Shp2 (Besset et al., 2000) and Shp2 
may act downstream of Spryl (Willecke et al., 2011) in the GDNF/RET signaling pathway, it is 
not surprising that the fold differences observed, for the genes tested, were similar in response to 
GDNF and serum stimulation (figure no.24). Expression of the genes increase with serum stimu­
lation and decreases in response to GDNF. These findings, show quantitatively minimal effect on 
Spryl, Shp2 and Etv4 expression in response to 4-hour GDNF treatment in the human SK-N-SH 
neuroblastoma cell line by real-time PCR. Our data, therefore, suggests that the fold difference is 
too discrete to alter the physiological state of the cell or for the cell to have to compensate for the 
change. The magnitude of the GDNF-RET signal, by 4-hour GDNF stimulation, is not trans­
duced to the nucleus to activate transcription of GDNF-RET dependent proteins. Finally, tran­
scription of these signaling proteins may not depend on RET activation alone. Future studies 
include analyzing transcriptional changes of these signaling proteins in response to RET activa­
tion with longer GDNF treatment times. Second, analyze the transcriptional changes of the sig­
naling proteins in response to RET activation with co-expression of different ligands including 
GDNF and TGF-fi. And third, the inclusion of biological replicates as opposed to technical repli­
cates. All of which should elicit a significant change in expression and thereby, contribute to un­
derstanding the role of RET in these RET-dependent signaling protein. In summary, the present 
findings contribute to elucidating the role of RET on downstream signaling and in cellular func­
tion.
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CLD1 CLD2 CLD3 CLD4 CRD TM JM Tyrosine Kinase Tail 9
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Ca 2+
Figure No. 1 Schematic representation of RET receptor tyrosine kinase 
The extracellular region of RET consists of four phylogenetically conserved cadherin-like do­
mains (CLD) that are each 110 residues long, including a calcium binding site between CLD2 and 
CED3, followed by a 120-residue cysteine rich domain (CRD) that is connected to the transmem­
brane domain (TM). The intracellular region of RET begins with a 50-residue juxtamembrane 
(JM) followed by a catalytic tyrosine kinase domain that is separated by a 14-residue linker region 
and ends with the 100-residue carboxyl terminal tail that results in two functional RET isoforms 
as a results of alternative splicing, RET 9 (short) and RET 51 (long).
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RET Receptor Tyrosine Kinase GDNF/GFRa 1 /RET
Proliferation Differentiation Migration Survival Metabolism
Figure No. 2 Schematic of Signaling Pathway Activity by the RET Receptor 
The RET receptor is represented as the green structure at the raft compartment of the plasma 
membrane. The assembly of the ligand, co-receptor and RET complex leads to dimerization. 
Dimerization allows each monomer to auto-phosphorylate the tyrosine residues in orange on the 
opposing monomer. Auto-phosphorylation activates the kinase activity of the receptor thereby 
signaling activation of other components downstream. The black arrows represent the putative 
pathways involving adaptor proteins, docking proteins, transcription factors and enzymes (left to 
right): growth factor receptor bound protein 2 (GRB2), Grb2 associated binding typel (GAB1), 
(AKT), lipid phosphoinositide 3-kinase (PI3K), phospholipase C gamma (PLC-y), protein kinase
C (PKG), protein tyrosine phosphatase, non-receptor type 11(PTPN11), (GRB2), sons of sevenless 
(SOS), extracellular signal-regulated kinase (Erk) and activation of mitogen-activated protein ki­
nase (MAPK), janus kinase and signal transducer and activation of transcription (JAK/STAT). 
The candidate genes are represented in grey at their presumed location based on gene knockout 
studies. The signal is transduced to the nucleus and transcription of growth-factor-responsive 
genes is activated. The possible cellular outcomes are highlighted at the bottom of the figure.
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Figure No. 3 Standard RT-PCR Primer Design for Candidate Genes (listed top to bottom) 
SPRY1 NM_001258038.1 - The forward and reverse primers both span an exon. The PCR 
product length is 194 base pairs. The forward primer parameters: 20 nucleotides, 55% GC con­
tent, and the melting temperature 62°C. The reverse primer parameters: 21 nucleotides 61% GC 
content, and the melting temperature 61°C.
PTPN11 (SHP2) NM_002834.3 - The primer was designed so that half of the forward primer 
hybridizes to the 3’ end of one exon and the 5’ end of the adjacent exon. The reverse primer 
spans an exon. The PCR product length is 135 base pairs. The forward primer parameters: 60% 
GC content, and the melting temperature 61°C. The reverse primer parameters: 60% GC con­
tent, and the melting temperature 60°C.
ETV4 NM_001986.2 - The forward primer spans an exon junction while the reverse spans an 
exon. The forward primer parameters: 18 nucleotides, 61% GC content, and the melting tem­
perature 59°C. The reverse primer parameters: 20 nucleotides, 55% GC content, and the melting 
temperature 55°C.
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Figure No. 4 Standard RT-PCR Primer Design for Housekeeping Genes (listed top to bottom) 
ACTB NM_001 101.3 - The forward and reverse primers both span an exon. The PCR product 
length is 100 base pairs. The forward primer parameters: 20 nucleotides, 65% GC content, and 
the melting temperature 61°C. The reverse primer parameters: 23 nucleotides, 43% GC content, 
and the melting temperature 60°C.
GAPDH NM_002046.3 - The forward and reverse primers flank an intron. The PGR product 
length is 100 base pairs. The forward primer parameters: 21 nucleotides, 57% GC content, and 
the melting temperature 61°G. The reverse primer parameters: 22 nucleotides, 40% GC content, 
and the melting temperature 59°C.
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Figure No. 5 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using undiluted 100ng/niL of RNA template and primer 
oligo(dT) followed by polymerase chain reaction with primers specific for GAPDH and [3-actin. 
The gel conditions are: 1% agarose gel in IX TBE ran at 100 volts for 45 minutes.
(1) DNA ladder
(2) GAPDH + reverse transcriptase
(3) GAPDH ‘ no reverse transcriptase’ control
(4) GAPDH ‘ no template’ control
(5) GAPDH + reverse transcriptase without Taq polymerase
(6) [3-actin + reverse transcriptase
(7) [3-actin ‘ no reverse transcriptase’ control
(8) |3-actin ‘ no template’ control
(9) [3-actin + reverse transcriptase without Taq polymerase
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Figure No. 6 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using undiluted 1 OOng/mL of RNA template using se­
quence - specific reverse primer followed by polymerase chain reaction with primers specific for 
Gapdh and (3-actin. The gel conditions are: 1% agarose gel in IX TBE ran at 100 volts for 45 
minutes.
(1) DNA ladder
(2) GAPDH + reverse transcriptase
(3) GAPDH ‘ no reverse transcriptase’ control
(4) GAPDH ‘ no template’ control
(5) GAPDH + reverse transcriptase without Taq polymerase
(6) (3-actin + reverse transcriptase
(7) (3-actin ‘ no reverse transcriptase’ control
(8) (3-actin ‘ no template’ control
(9) (3-actin + reverse transcriptase without Taq polymerase
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Figure No. 7 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed using (left) 1 in 10 diluted 100ng/mL RNA template and 
(right) 1 in 5 diluted 1 OOng/mL RNA template with the (3-actin reverse primer followed by poly­
merase chain reaction with primers specific for (3-actin. The gel conditions are: 1.5% agarose gel 
in 1XTBE ran at 100 volts for 45 minutes.
(1) DNA ladder
1 in 10 diluted lpg/uL of RNA template.
(2) |3-actin + reverse transcriptase
(3) (3-actin ‘no reverse transcriptase’ control
(4) (3-actin ‘no template’ control
1 in 5 diluted lpg/uL of RNA template.
(5) (3-actin + reverse transcriptase
(6) (3-actin ‘no reverse transcriptase’ control
(7) (3-actin ‘no template’ control
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Figure No. 8 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed with (left) undiluted lOOng/mL RNA template and (right) 1 in 
10 diluted 100ng/niL RNA template using sequence-specific reverse primers followed by poly­
merase chain reaction with primers specific for Etv4, Spryl and and (i-actin. The gel conditions 
are: 1% agarose gel in IX TBE ran at 100 volts for 45 minutes.
(1) DNA ladder
(2) Etv4 + reverse transcriptase
(3) Etv4 ‘no reverse transcriptase’ control
(4) Spryl + reverse transcriptase
(5) Spryl ‘no reverse transcriptase’ control
(6) (3-actin + reverse transcriptase
(7) P-actin ‘no reverse transcriptase’ control
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Figure No. 9 Gel Electrophoresis: Agarose gel of RT-PCR product 
Reverse transcriptase was performed using 1 in 5 diluted 1 OOng/mL of RNA template and 
(left) sequence-specific reverse primer or (right) primer oligo(dT) followed by polymerase chain 
reaction with primers specific for P-actin. The gel conditions are: 1.5% agarose gel in IX TBE 
ran at 100 volts for 45 minutes.
(1) DNA ladder 
Sequence-specific reverse primer
(2) [3-ac.tin + reverse transcriptase
(3) p-actin ‘no reverse transcriptase’ control
(4) P-actin ‘no template’ control
(5) P-actin + reverse transcriptase without Taq polymerase 
Primer oligo(dT)
(6) p-actin + reverse transcriptase
(7) p-ac.tin ‘no reverse transcriptase’ control
(8) P-actin ‘no template’ control
(9) P-actin + reverse transcriptase without Taq polymerase
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Figure No. 10 Gel Electrophoresis: Agarose gel of RT-PGR product
Reverse transcriptase was performed with 1 in 5 diluted 1 OOng/mL RNA template using se­
quence-specific reverse primers followed by polymerase chain reaction with primers specific for fi- 
actin, Etv4, GAPDH and Shp2. The gel conditions are: 1% agarose gel in IX TBE ran at 100 
volts for 45 minutes.
(1) DNA ladder
(2) [3-actin + reverse transcriptase
(3) |3-actin ‘no reverse transcriptase’ control
(4) Etv4 + reverse transcriptase
(5) Etv4 ‘no transcriptase’ control
(6) GAPDH + reverse transcriptase
(7) GAPDH ‘no reverse transcriptase’ control
(8) Shp2 + reverse transcriptase
(9) Shp2 ‘no transcriptase’ control
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Figure No. 11 Gel Electrophoresis: Agarose gel of RT-PCR product
Reverse transcriptase was performed with 1 in 5 diluted lOOng/mL of RNA template using se­
quence specific reverse primers followed by polymerase chain reaction with primers specific for p- 
actin, Spry 1, GAPDH, and Shp2. The gel conditions are: 1% agarose gel in IX TBE ran at 100 
volts for 45 minutes.
(1) DNA ladder
(2) p-actin + reverse transcriptase
(3) P-actin ‘no reverse transcriptase’ control
(4) Spryl + reverse transcriptase
(5) Spryl ‘no transcriptase’ control
(6) GAPDH + reverse transcriptase
(7) GAPDH ‘no reverse transcriptase’ control
(8) Shp2 + reverse transcriptase
(9) Shp2 ‘no transcriptase’ control
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Figure No. 12 Real-Time PCR using SYBR Green
The real-time PCR reaction was performed as two-step reaction. The reverse transcriptase reac­
tion was performed with gene-specific reverse primers for Spryl and P-actin using 1 in 5 diluted 
100ng/mL RNA. The polymerase chain reaction with cDNA and SYBR green was carried out 
subsequently in a separate reaction tube. The amplification plot shows the fluorescence signal 
versus the cycle number. The normalized reported (Rn) is the ratio of the fluorescence emission 
of the reporter dye to the fluorescence emission of the passive dye. The baseline refers to the ini­
tial cycles of the reaction where there is minimal change fluorescence signal. The (ARn) is the 
baseline subtracted from the Rn. The cycles represent the cycles as the polymerase chain reaction 
progresses. Spryl is represented by the yellow line and P-actin is represented by the green line. 
The ‘+ reverse transcriptase’ control for Spryl resulted in a Ct value of 37.07, the ‘no reverse 
transcriptase’ 21.89, and the ‘no template’ control resulted in a Ct value of 34.02. The ‘+ reverse 
transcriptase’ control for P-actin resulted in a Ct value of 14.5, the ‘no reverse transcriptase’ con­
trol, 36.01 and the ’no template’ control 26.87.
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Real-Time qPCR TaqMan Average Ct Values
Gapdh ß-actin Spryl Shp2 Etv4
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Figure No. 13 Average Ct value of RET dependent signaling proteins
Technical replicates were used for the Real-Time qPCR TaqMan reactions as opposed to biologi­
cal replicates. Three replicates were used to control for validity of the method. The average and 
± standard deviations of the replicates are presented as statistical validation for the replicates test­
ed. The bar height indicates the average expression of each gene in response to the three experi­
mental conditions: (serum-free) untreated, 4-hr serum treatment and 4-hr GDNF treatment.
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Figure No. 14 The A in Ct Average of RET dependent signaling proteins 
The bar height represent the A in Ct Average that is calculated by subtracted the average Ct of 
the endogenous control form the average Ct of the target gene. The three bar per gene represent 
the experimental conditions, (serum-free) untreated, 4-hr serum treatment and 4-hr GDNF treat­
ment, respectively. The top graph represents the A in Ct average for GAPDH. The bottom 
graph represent the A in Ct Average for [3-actin.
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Table No. 1 Data Normalized to [3-actin relative to treatment using Livak AACt Method 
Relative quantification of gene expression measures the differences in expression levels of a target 
between samples. It is the change in expression of a target in a sample relative to the same target 
in a reference sample. The table represents the separate real-time qPCR experiments performed 
with TaqMan gene expression assays that were normalized to p-actin. The data is presented as 
the experimental conditions followed by the averages with ± standard deviations of the three 
technical replicates. The data is read as a fold-difference of expression levels. The amplification 
efficiency of the assays are listed on the right.
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Figure No. 15 Standard Curve for J3-actin
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 16 Standard Curve for Spryl
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 100ng/niL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
lOOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend. The 0.0 IX values are not plotted in the curve.
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Figure No. 17 Standard Curve for Shp2
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 1 OOng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
1 OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 18 Standard Curve for Etv4
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 1 OOng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 19 Data Normalized to (3-actin relative to treatment using Livak AACt Method 
Real-time PCR analysis of the expression levels using predesigned TaqMan gene expression as­
says. Data was normalized to ff-actin. The values represent fold changes relative to the untreated 
(serum-free) control and are given as the fold difference with ± standard deviations and p values. 
The values are presented as relative fold changes with upregulation > 1 and downregulation < 1.
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Table No. 2 Data Normalized to GAPDH relative to treatment using Livak AACt Method 
Relative quantification of gene expression measures the differences in expression levels of a target 
between samples. It is the change in expression of a target in a sample relative to the same target 
in a reference sample. The table represents the separate real-time PCR experiments performed 
with TaqMan gene expression assays that were normalized to GAPDH. The data is presented as 
the experimental conditions followed by the averages with ± standard deviations of the three 
technical replicates. The data is read as a fold-difference of expression levels. The amplification 
efficiency of the assays are listed on the right.
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Figure No. 20 Standard Curve for GAPDH
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 1 OOng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0. IX) 
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 21 Standard Curve for Spryl
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
1 OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 22 Standard Curve for Shp2
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 1 OOng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
100ng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned' in the legend.
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Figure No. 23 Standard Curve for Etv4
The amplification efficiency of real-time PCR assays were assessed by standard curves construct­
ed with serial dilutions of the 100ng/mL RNA template extracted from SK-N-SH untreated 
(serum-free) neuroblastoma cells. The Ct versus the RNA concentration (log scale) are plotted to 
calculate slope and R2 value. The experimental conditions were tested with 1 in 10 diluted (0.1X) 
1 OOng/mL untreated RNA template. The replicates for the dilutions are plotted as the grey boxes 
labeled ‘not assigned’ in the legend.
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Figure No. 24 Data Normalized to GAPDH relative to treatment using Livak AACt Method 
Real-time PGR analysis of the expression levels using predesigned TaqMan gene expression as­
says. Data was normalized to GAPDH. The values represent fold changes relative to the un­
treated (serum-free) control and are given as the fold difference with ± standard deviations and p 
values. The values are presented as relative fold changes with upregulation > 1 and downregula- 
tion < 1.
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